35 stories found
A comparative analysis examines the investment potential of Incyte Corporation and Revolution Medicines as both companies pursue promising KRAS-targeted therapies in the competitive biotech sector.
The Global Vitiligo Foundation has applauded Incyte's “Moments of Clarity” campaign for its efforts in elevating patient voices and advancing vitiligo awareness.
Several companies, including NOV, Chemed, Seagate Technology, and Mondelēz, have reported their Q2 2026 earnings, with many beating analyst expectations, while others like DMC Global and Public Storage have released Q2 2026 earnings previews.
Incyte is positioning itself as a strong contender for biotech growth, making its case against established players like Regeneron.
The United Nations has announced that over 50,000 people are missing in Venezuela following recent earthquakes, with the death toll exceeding 900. This comes as the EU continues various activities, including backing a Rett syndrome therapy and holding energy talks with Iraq.
Mirum and Incyte have reported positive results from their Phase 2 clinical trial for zilurgisertib, a drug being developed for the treatment of Fibrodysplasia Ossificans Progressiva (FOP).
Incyte is reportedly nearing a deal worth up to $2 billion to acquire Star Therapeutics, a developer of drugs for blood disorders. This acquisition would significantly expand Incyte's portfolio in the blood disorder treatment market.
Incyte-Genesis has expanded its AI drug discovery deal, securing $120 million in funding and identifying new targets for research.
Analysts reaffirm stock ratings for Incyte (INCY), noting the company's strategic positioning to mitigate risks associated with upcoming patent expirations.
Shimmick has appointed a new Chief Operating Officer, while Incyte has tapped Zimmer Biomet's Suketu Upadhyay as its new Chief Financial Officer. These announcements reflect recent leadership changes within the companies.
Incyte has announced several changes to its executive leadership team, detailing new appointments within its leadership structure.
Incyte Corp. reported a 28% year-over-year revenue growth to $1.51 billion in Q4 2025, primarily fueled by sales of Jakafi and Opzelura.
Multiple executives from various companies, including Tempus AI, Snowflake, and Crowdstrike, have engaged in significant stock transactions, with some selling millions in shares while others made purchases.
Incyte has experienced significant sales growth, which has directly contributed to an increase in its share price, reflecting positive investor sentiment.
Halozyme has announced a deal with Incyte to utilize its Enhanze technology for a candidate targeting neoplasms.
Truist has increased its price target for Incyte (INCY) to $105, attributing the adjustment to a government settlement that added $246 million to the company's net sales.
A summary of the best Wall Street analyst research calls for Monday, featuring companies like Accenture, Apple, Boyd Gaming, BWX Technologies, Conoco-Phillips, Estee Lauder, Hut 8, Incyte, and SpaceX.
A weekly summary of significant business deals highlights transactions involving companies such as GSK, Incyte, Ingredion, and OpenAI, among others.
A new lymphoma therapy developed by Incyte has demonstrated a 25% increase in cancer-free survival rates during a late-stage clinical trial. This positive outcome suggests a significant advancement in treatment options for lymphoma patients.
Analysts have provided their latest estimates and ratings for Incyte stock, offering insights into the company's financial outlook and potential market performance. Investors are reviewing these assessments for investment decisions.
Incyte has projected its 2026 net sales to be between $4.77 billion and $4.94 billion and is preparing to launch four new products within the next 12 months.
Adagene (ADAG) has announced a partnership with Incyte (INCY) to evaluate a combination therapy for the treatment of colorectal cancer.
Analysts are providing their assessments on where Incyte Corporation (INCY) is headed, offering insights into its prospects.
Analysts on Wall Street are divided on whether to be bullish or bearish on Incyte stock, prompting discussions among investors.
South Korean technology stocks, particularly chip manufacturers, experienced significant declines amid growing skepticism about the AI market and an extended chip rout. SK Hynix shares were notably affected, deepening their decline due to an earnings miss, excessive leverage by retail investors, and fears of Chinese competition.
Incyte is set to release its second-quarter 2026 earnings report. Analysts and investors are anticipating the financial results and company outlook.
Shares of biopharmaceutical company Incyte are showing signs of a breakout, moving out of a seven-month trading range, according to analyst Carter Worth.
An article provides an analysis of Incyte stock, examining whether INCY is outperforming the broader healthcare sector.
Johnson & Johnson is set to acquire cancer drug technology developer Firefly Bio for $1 billion, while Incyte announced its acquisition of Vega Therapeutics for $1.25 billion. These deals highlight significant activity in the pharmaceutical and biotechnology sectors.
Incyte has finalized a $120 million deal focused on utilizing artificial intelligence for drug development.
Incyte Corporation (INCY) announced sustained efficacy results for its drug Opzelura, demonstrated through week 24 of studies.
Key highlights from Incyte's first-quarter earnings call have been released.
RBC Capital has raised its price target for Incyte Corporation (INCY) from $92 to $95. This upward adjustment reflects a more positive financial outlook for the biopharmaceutical company.
Incyte Announces The European Commission Approval Of Zynyz® (retifanlimab) For The First-Line Treatment Of Advanced Squamous Cell Carcinoma Of The Anal Canal (SCAC) TradingView